Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mentice ABOSTO:MNTC -3.23%71 3-Year ROIIC % is 26.22 as of Dec. 2025, which is 139% above its 10-year median of 10.97. GuruFocus rates OSTO:MNTC with a GF Score™ of 71/100 and a GF Value™ of kr26.10 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Mentice AB ranks better than 74.21% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Mentice AB's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 26.22%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Mentice AB's 3-Year ROIIC % or its related term are showing as below:
OSTO:MNTC's 3-Year ROIIC % is ranked better than 74.21% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 1.47
vs OSTO:MNTC: 26.22
Mentice AB (OSTO:MNTC) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Mentice AB 3-Year ROIIC % Related Terms
Mentice AB 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Mentice AB's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:MNTC vs ABT, SYK, MDT: 3-Year ROIIC % Comparison
For the Medical Devices subindustry, Mentice AB's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mentice AB 3-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Mentice AB's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Mentice AB's 3-Year ROIIC % falls into.
Mentice AB's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -31.435 (Dec. 2025) - -24.858 (Dec. 2022) )
/
( 290.184 (Dec. 2025) - 315.271 (Dec. 2022) )
=
-6.577
/
-25.087
=
26.22%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Mentice AB (OSTO:MNTC) has a 3-Year ROIIC % of 26.22 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Mentice AB and its competitors. This is 139% above median its historical median of 10.97. According to the industry distribution chart, Mentice AB ranks #205 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 25.8%.
Is Mentice AB's 3-Year ROIIC % too high?
Mentice AB's current 3-Year ROIIC % of 26.22 is 139% above median its 10-year median of 10.97. The Medical Devices & Instruments industry median 3-Year ROIIC % is 1.47. Mentice AB's value of 26.22 is 1683.7% above this industry median. Based on the distribution chart, Mentice AB ranks #205 out of 795 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Mentice AB has a GF Score™ of 71/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mentice AB's 3-Year ROIIC % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Mentice AB ranks #205 out of 795 companies for 3-Year ROIIC %. This puts Mentice AB in the upper half of its industry. The industry median 3-Year ROIIC % is 1.47. Mentice AB's value of 26.22 is 1683.7% above this benchmark. While the company's 10-year median is 10.97 vs. the industry median of 1.47, Mentice AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Devices & Instruments company?
The median 3-Year ROIIC % among Medical Devices & Instruments companies is 1.47, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mentice AB's current 3-Year ROIIC % of 26.22 is 1683.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Mentice AB and its competitors. For the Medical Devices & Instruments industry, the median 3-Year ROIIC % is 1.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mentice AB's current 3-Year ROIIC % is 26.22, which is 139% above median its own 10-year median of 10.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mentice AB stock overvalued right now?
Based on GuruFocus' analysis, Mentice AB (OSTO:MNTC) is currently considered Possible Value Trap. The stock's GF Value™ is kr26.10, compared to a current price of kr13.50 — trading 48.3% below its estimated fair value. The current 3-Year ROIIC % is 26.22, which is 139% above median its 10-year median of 10.97 and 1683.7% above the Medical Devices & Instruments industry median of 1.47. Mentice AB's overall GF Score™ is 71/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Mentice AB (OSTO:MNTC), the current 3-Year ROIIC % is 26.22 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mentice AB (OSTO:MNTC) Overvalued in 2026?
Based on GuruFocus' analysis, Mentice AB stock appears to be undervalued.
The current stock price of kr13.50 is trading 48.3% below its estimated GF Value™ of kr26.10.
GuruFocus considers Mentice AB to be Possible Value Trap.
Key valuation signals for OSTO:MNTC:
3-Year ROIIC %: 26.22 (139% above median its 10-year median of 10.97)
GF Value™: kr26.10 vs. price of kr13.50 (48.3% below fair value)
Industry Position: 1683.7% above the Medical Devices & Instruments median (#205 of 795)
No single metric tells the full story. See the OSTO:MNTC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mentice AB is a provider of software and hardware simulation solutions for image guided interventional therapies, offering proficiency based simulation solutions that help healthcare professionals acquire, retain, and enhance procedural skills, improving productivity and outcomes. Its solutions are scientifically validated and developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular, and peripheral interventions are covered. Mentice operates in two segments: Medical Device Industry (MDI), providing end-to-end solutions supporting development and launch of interventional therapies, and Healthcare Systems (HCS). Product areas include Mentice VIST, Physical Sim, Mentice Live, and Ankyras. It operates in EMEA, APAC, and the Americas.
71GF Score
Get the complete analysis for OSTO:MNTC
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:MNTC has been successfully added to your 
